@article{a38a1fe0806f4b55a9eb5572a152db9c,
title = "Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis",
abstract = "Fingolimod is an effective disease modifying therapy for multiple sclerosis (MS). Beyond its main action on peripheral lymphocytes, several noteworthy side effects have been demonstrated in vitro, among which modulation of neural excitability. Our aim was to explore cortical excitability in vivo in patients treated with fingolimod 0.5mg/day.",
keywords = "Administration, Oral, Adult, Animals, Evoked Potentials, Motor, Female, Fingolimod, Fingolimod Hydrochloride, Glutamate, Glutamic Acid, Humans, Immunosuppressive Agents, Intracortical facilitation, Male, Middle Aged, Motor Cortex, Motor cortex, Multiple Sclerosis, Relapsing-Remitting, Multiple sclerosis, Propylene Glycols, Prospective Studies, Sphingosine, Transcranial Magnetic Stimulation, Transcranial magnetic stimulation, Administration, Oral, Adult, Animals, Evoked Potentials, Motor, Female, Fingolimod, Fingolimod Hydrochloride, Glutamate, Glutamic Acid, Humans, Immunosuppressive Agents, Intracortical facilitation, Male, Middle Aged, Motor Cortex, Motor cortex, Multiple Sclerosis, Relapsing-Remitting, Multiple sclerosis, Propylene Glycols, Prospective Studies, Sphingosine, Transcranial Magnetic Stimulation, Transcranial magnetic stimulation",
author = "D. Landi and S. Vollaro and G. Pellegrino and D. Mulas and Delia Mulas and A. Ghazaryan and E. Falato and P. Pasqualetti and Patrizio Pasqualetti and Rossini, {P. M.} and Rossini, {Paolo Maria} and Filippi, {M. M.}",
year = "2015",
doi = "10.1016/j.clinph.2014.05.031",
language = "English",
volume = "126",
pages = "165--169",
journal = "Clinical Neurophysiology",
issn = "1388-2457",
publisher = "Elsevier Science Ireland Limited:PO Box 85, Limerick Ireland:011 353 61 709600, 011 353 61 61944, EMAIL: usinfo-f@elsevier.com, INTERNET: http://www.elsevier.com, Fax: 011 353 61 709114",
}